© Copyright - Newspaper WordPress Theme by TagDiv
Medroxyprogesterone Acetate
Also known as / Synonyms: MPA, Medroxyprogesterone, Depot Progestin
Oral and injectable progestin that induces regular periods in absent menses and provides long-acting birth control.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance without organic pathology.
- Reduction of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens (endometrial protection).
- Long-acting female contraception (Depo-Provera 150 mg IM injection every 12 weeks).
- Adjunctive and palliative treatment of inoperable, recurrent, and metastatic endometrial carcinoma or renal cell carcinoma (high-dose oncology regimens).
Contraindications (Do Not Use If…)
- Known or suspected pregnancy.
- Active or past history of thromboembolic disorders or stroke.
- Known or suspected carcinoma of the breast or genital organs.
- Undiagnosed abnormal vaginal bleeding.
- Severe liver dysfunction or hepatic disease.
- Missed abortion.
Important Clinical Precautions & Warnings
- Bone mineral density (BMD) loss: prolonged use of injectable depot medroxyprogesterone (Depo-Provera) causes progressive loss of bone mineral density, which may not be completely reversible; evaluate bone density in long-term users (> 2 years).
- Withdrawal bleeding expectations: oral administration for secondary amenorrhea is typically given for 5 to 10 days; withdrawal bleeding usually begins within 3 to 7 days after stopping the tablets.
- Thromboembolic events: monitor for symptoms of pulmonary embolism, deep vein thrombosis, and retinal thrombosis; discontinue immediately if suspected.
- Fluid retention and depression: can cause significant fluid retention, weight gain, and depressive mood swings; monitor closely in patients with clinical depression.
- Carbohydrate and lipid metabolism: can decrease glucose tolerance and increase LDL/HDL ratio; monitor diabetic patients.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Injectable depot formulation is not recommended as first-line in growing adolescents due to concerns regarding peak bone mass acquisition. Geriatric: Use in postmenopausal women strictly in combination with estrogens for endometrial protection.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Breakthrough bleeding, spotting, amenorrhea, weight gain, breast tenderness, nausea, headache, acne, and peripheral edema.
Serious Side Effects — Seek Urgent Medical Care
Deep vein thrombosis, pulmonary embolism, stroke, permanent bone mineral density loss (depot injection), severe depression, and anaphylactic reactions.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Hepatic enzyme inducers (carbamazepine, phenytoin, rifampin, phenobarbital): increase MPA clearance and decrease progestational efficacy.
- Anticoagulants: may alter prothrombin time and anticoagulant response.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
Contraindicated during pregnancy (FDA Category X). Progestin exposure during the first four months of pregnancy carries potential risk of minor congenital anomalies, including hypospadias in male infants.
Lactation & Breastfeeding:
Medroxyprogesterone is excreted in breast milk in small amounts, but does not adversely affect infant growth or lactation performance. It is commonly used as a postpartum contraceptive starting 6 weeks after delivery.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store tablets at 20°C to 25°C (68°F to 77°F). Protect from excessive moisture.
⏱️ Missed Dose Protocol:
Take the missed oral tablet as soon as remembered. If close to the next scheduled daily dose, skip and resume regular schedule. For depot injections, administer within 13 weeks to maintain continuous contraception.
Overdose produces nausea, vomiting, breast tenderness, and vaginal withdrawal bleeding. Supportive symptomatic care is sufficient.
